tm logo
AMZIJAY
Live/Pending
RESPONSE AFTER NON-FINAL ACTION - ENTERED

final action

on 18 Dec 2024

Last Applicant/ Owned by

Route 206 & Province Line Road

Princeton

NJ

08543

Serial Number

98290537 filed on 29th Nov 2023

Registration Number

N/A

Correspondent Address

Xiomara Triana

Xiomara Triana Bristol-Myers Squibb Company

Trademark Dept., Mailstop D.4243

Princeton, NJ 08648-4000

United States

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

AMZIJAY

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloprol Read More

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs being pharmaceutical preparations for the treatment of cancer; anticoagulants; Pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy for the treatment of cancer; Pharmaceutical and biological preparations for human use, namely, stem cells for medical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; diagnostic preparations for human use for medical purposes; radiopharmaceutical preparations for human use in the nature of imaging and detection agents for diagnosing and monitoring cancer; biological preparations for human use in the nature of radio-isotope markers for therapeutic or diagnostic use; Pharmaceutical preparations for human use for the treatment of cystic fibrosis.


First Use Date in General

N/A

First Use Date in Commerce

N/A

Mark Details


Serial Number

No 98290537

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 00163038-US

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
18th Dec 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
18th Dec 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
18th Dec 2024TEAS/EMAIL CORRESPONDENCE ENTERED
18th Sep 2024NON-FINAL ACTION WRITTEN
18th Sep 2024NON-FINAL ACTION E-MAILED
18th Sep 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
11th Sep 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
11th Sep 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
11th Sep 2024TEAS/EMAIL CORRESPONDENCE ENTERED
13th Jun 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED